James Bullington,
Dennis Argentieri, Kristin Averill,
Demetrius Carter,
Druie Cavender,
Bohumila Fahmy,
Xiaodong Fan,
Daniel Hall,
Geoffrey Heintzelman,
Paul Jackson, [......],
Gilbert Olini,
Thomas Razler,
Michael Reuman,
Kenneth Rupert,
Ronald Russell,
John Siekierka,
Scott Wadsworth,
Russell Wolff,
Bangping Xiang,
Yue-Mei Zhang
[show abstract]
[hide abstract]
ABSTRACT: Inhibition of the p38 map kinase pathway has been shown to be beneficial in the treatment of inflammatory diseases. The first class of potent p38 kinase inhibitors was the pyridinylimidazole compounds from SKB. Since then several pyridinylimidazole-based compounds have been shown to inhibit activated p38 kinase in vitro and in vivo. We have developed a novel series of pyridinylimidazole-based compounds, which potently inhibit the p38 pathway by binding to unactivated p38 kinase and only weakly inhibiting activated p38 kinase activity in vitro.
Bioorganic & Medicinal Chemistry Letters 01/2007; 16(23):6102-6. · 2.55 Impact Factor
